LIEGE, Belgium, Nov. 8, 2011 /CNW/ - PREMICE clinical trial proves
Cefaly(R) medical device efficacy in migraine prevention and points out
that Cefaly(R) has the best safety-efficacy ratio compared to other
On Monday 7th of November a press conference took place in Liege Science
Park. Professor Jean Schoenen, principal investigator, neurologist and
professor at Liege University (Belgium) presented the results of
PREMICE (Prevention Migraine Cefaly) a multicenter randomized
double-blind placebo controlled clinical trial for migraine prevention
with the Cefaly(R) neurostimulator.
The clinical trial was conducted in 5 Belgian university hospitals on 67
patients. The results prove the efficacy of the Cefaly(R) compared to
placebo for migraine prevention. At 3 months of treatment the 50%
responder rate was significantly greater in the Cefaly(R) group (38,1%)
than in the placebo group (12,1%). Seventy percents of patients
declared they were satisfied or very satisfied with the Cefaly(R)
treatment. The drug consumption reduction is very impressive in the
Cefaly(R) group (-37%) compared to the placebo group (+0.5%). Cefaly(R)
responder group drug consumption reduction was -75%!
Without noticeable side effects or contraindications, Cefaly(R) is very
safe. Cefaly(R) has a similar efficacy than preventative drugs, but
without side effects. Consequently, Cefaly(R) has the best
safety-efficacy ratio of all migraine treatments.
Prof. Schoenen: "This clinical trial has been implemented according to
the highest quality standard and it proves that Cefaly(R) is efficient
for migraine prophylaxis. Efficacy is similar with the most efficient
preventative drugs but with the great advantage of having no side
Cefaly(R) is an innovative medical device protected by a series of
patents. This is the first cranial external neurostimulation device on
the market. Cefaly(R) neurostimulation is applied to the upper branch
of the trigeminal nerve. A self-adhesive electrode is applied on the
forehead and the device is placed on this electrode in the position of
a pair of glasses. Very accurate pulses are transmitted through the
electrode to the nerve endings of the trigeminal nerve.
STX-Med Company is a startup based in Liege (Belgium), which launched
the Cefaly(R) technology project in 2005. The company STX-Med is ISO
Medical. Cefaly(R) device has the medical CE-marked. It is available on
the European market for 295 EUR and in Canada as well.
For further information:
STX-Med, ZI des Hauts Sarts, 4eme Avenue NÂ°5, B-4040, Herstal, Liège, Belgium, Phone: +32-43676722, Fax: +32-43676702, firstname.lastname@example.org; Press Contact Dr Pierre Rigaux, Mobile: +32-475413698, email@example.com